Replies to post #11076 on Aurinia Pharmaceuticals Inc (AUPH)

[slimhere]

John Thero over at Amarin is a CPA that was at the right place at the right time, but man oh man, have you ever heard him speak. He's way over his head, and doesn't know it. Thero is over there, and this is Aurinia. You can tell me, Thero has one employee in Europe, and he's feels it's best for shareholder value to GIA, perhaps you can guess if he's a Dick, Prick or straight up Dickhead. For what it's worth, anyone taking a statin, should IMO, also be taking Vascepa.

ZZ, it should have been clear, that several of my posts were tongue in cheek, the fact that I received the answer to my question does move the man up, it's that simple.

If you recall, I wanted to start a dialogue with IR, I've accomplished that. Next year, after the FDA shindig, I'll get back in touch with my "buddy". If everyone is lucky, until then, I'll climb back under my rock.

Good Luck, to you.

[north40000]

AMRN reportedly looking at an “authorized generic” version of Vascepa, in addition to branded version. Same drug and label, 2 different names and prices(Brand Vascepa for reduction of risk of CVD is $36/year out of pocket for me since mid-2018). Let’s see whether and how generics compete—no entry into market place yet in the Marine market. Generics hope for off label prescriptions and sales into CVD space; Marine market/revenue is relatively small.

Vascepa also has a statutory exclusivity (resulting from FDA approving its sNDA for results in CVDs demonstrated in 8000+ patient Reduce-It trial last 12/2020) that expires 12/2022. It is independent of any RI patents (numbering >40-50 at last count) that expire 2030 and later.

Our LTCG in Amarin far exceeds our LTCG in AUPH(we have 65x more shares of AMRN than 2k AUPH). Basis for AUPH shares = $1.94.